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AbstrAct
Introduction Invasive infections caused by Salmonella 
enterica serovar Typhi and Paratyphi A are estimated 
to account for 12–27 million febrile illness episodes 
worldwide annually. Determining the true burden of 
typhoidal Salmonellae infections is hindered by lack 
of population-based studies and adequate laboratory 
diagnostics. The Strategic Typhoid alliance across Africa 
and Asia study takes a systematic approach to measuring 
the age-stratified burden of clinical and subclinical disease 
caused by typhoidal Salmonellae infections at three 
high-incidence urban sites in Africa and Asia. We aim to 
explore the natural history of Salmonella transmission in 
endemic settings, addressing key uncertainties relating 
to the epidemiology of enteric fever identified through 
mathematical models, and enabling optimisation of 
vaccine strategies.
Methods/design Using census-defined denominator 
populations of ≥100 000 individuals at sites in Malawi, 
Bangladesh and Nepal, the primary outcome is to 
characterise the burden of enteric fever in these populations 
over a 24-month period. During passive surveillance, 
clinical and household data, and laboratory samples will 
be collected from febrile individuals. In parallel, healthcare 
utilisation and water, sanitation and hygiene surveys will be 
performed to characterise healthcare-seeking behaviour 
and assess potential routes of transmission. The rates of 
both undiagnosed and subclinical exposure to typhoidal 
Salmonellae (seroincidence), identification of chronic 
carriage and population seroprevalence of typhoid infection 
will be assessed through age-stratified serosurveys 
performed at each site. Secondary attack rates will be 
estimated among household contacts of acute enteric fever 
cases and possible chronic carriers.
Ethics and dissemination This protocol has been 
ethically approved by the Oxford Tropical Research Ethics 
Committee, the icddr,b Institutional Review Board, the 
Malawian National Health Sciences Research Committee 
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Protocol
Strengths and limitations of this study
 ► The study is designed with a comprehensive 
multicomponent epidemiological approach, 
nesting passive surveillance, serosurveillance and 
healthcare utilisation surveys within a demographic 
census population to accurately determine the age-
stratified burden of enteric fever.
 ► The diversity of field sites in Africa and Asia will provide 
data on typhoid epidemiology and transmission from 
a range of differing epidemiological settings.
 ► The combination of a traditional epidemiological 
approach with novel laboratory methods for the 
diagnosis of febrile illness and investigation of 
the host and pathogen genetics and antimicrobial 
resistance determinants provides a unique platform 
to study this disease.
 ► Practical limitations include the sharing and 
standardisation of clinical definitions, data and 
sample collection methods and laboratory assays, 
based on the facilities and staff available and 
community requirements at each site.
 ► The number of field  sites included in this current 
protocol is limited to three; all of these sites are 
densely populated urban settings with likely 
high  incidence of enteric fever transmission. The 
degree to which our data may be extrapolated to 
other settings and countries remains to be explored.
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and College of Medicine Research Ethics Committee and Nepal Health 
Research Council. The study is being conducted in accordance with 
the principles of the Declaration of Helsinki and Good Clinical Practice. 
Informed consent was obtained before study enrolment. Results will 
be submitted to international peer-reviewed journals and presented at 
international conferences.
Trial registration number ISRCTN 12131979.
Ethics references Oxford (Oxford Tropical Research Ethics 
Committee 39-15). Bangladesh (icddr,b Institutional Review Board 
PR-15119). Malawi (National Health Sciences Research Committee 
15/5/1599). Nepal (Nepal Health Research Council 306/2015).
Background
Salmonella enterica serovars Typhi (S Typhi) and Para-
typhi A (S Paratyphi A) are human-restricted pathogens 
transmitted by faeco-oral ingestion. The ensuing disease, 
enteric fever (or ‘typhoid fever’), is a non-specific febrile 
illness which affects an estimated 12–27 million people 
worldwide each year, resulting in 129 000–223 000 
deaths.1–3 Despite a dramatic reduction in incidence over 
the last century in most high-income countries, continuing 
inadequate access to clean water and increasing inter-
continental spread of multiply antibiotic-resistant strains 
hampers disease control efforts, especially in resource-lim-
ited settings.3–5 The current burden of disease is highest 
among children and young adults in South and South-
east Asia1–3 but is increasingly recognised in sub-Saharan 
Africa.6
Recently, a new generation of Vi-conjugate enteric fever 
vaccines, suitable for use in infants and providing longer-
lasting protection than those previously licensed,7–10 have 
become available. Determining how and where interven-
tions such as vaccination may be best deployed is difficult 
due to a lack of population-based incidence studies and 
inaccurate diagnostic tests.1–3 Improving disease burden 
estimates and providing data on the epidemiology and 
transmission of S Typhi and S Paratyphi A to inform 
mathematical models11–13 could improve the evidence 
necessary to design comprehensive and effective disease 
control programmes.14
Burden of disease and diagnostics
Recent meta-analyses examining global causes of 
morbidity and mortality estimate that a significant 
burden of disease worldwide, and especially in South and 
Southeast Asia, may be attributed to enteric fever.15–17 
The margin of error on these estimates is wide, however; 
much of the uncertainty regarding the burden of disease 
caused by typhoidal Salmonella is due to the unavailability 
of accurate diagnostics or misclassification of non-spe-
cific disease presentations, in addition to a general lack 
of data.18 Availability of antibiotics from local pharmacies 
without prescription, frequent misdiagnosis as malaria, 
dengue or other febrile illnesses, or the avoidance of 
hospital due to fear or expense are all likely to result in an 
underestimate of the true numbers of cases.19 In contrast, 
the widespread use of suboptimal diagnostic tests such as 
the Widal test in areas where exposure to similar bacteria 
in the environment occurs may lead to inaccurate overdi-
agnosis of the condition.20 Previous studies and systematic 
reviews have attempted to address this inaccuracy by 
calculating the imprecision associated with insensitive 
blood culture methods, and applying this correction to 
blood culture confirmed case numbers.1 2
In addition to a better understanding of the disease 
burden attributable to typhoidal Salmonellae, improved 
diagnostics and biomarkers are required to improve indi-
vidual case management.21 The current gold-standard 
diagnostic test for typhoid/paratyphoid is blood culture; 
while this test provides the causative isolate, thereby 
allowing susceptibility testing and further typing methods 
to be performed, most laboratories in resource-limited 
settings lack the infrastructure to perform these assays. 
Even in ideal conditions, blood culture requires a signif-
icant volume of blood to enhance diagnostic yield and 
is relatively insensitive even in highly controlled human 
challenge settings where sensitivity reaches 80%.22 
Highly sensitive and specific diagnostic tests are a funda-
mental requirement for surveillance and vaccine efficacy 
studies, however, both for measuring the number of cases 
avoided/prevented, but also for reassuring policymakers 
and funders that vaccine implementation is worth invest-
ment. While several rapid serological diagnostic tests 
have recently been developed, these still rely on a few 
selected antigens, which are known to be non-specific in 
endemic communities.23 24 Newer diagnostic modalities 
are in development, however, which have used serum 
banks from multiple countries and samples collected 
from controlled human infection models to identify 
putative novel antigens for serological assay and further 
high-sensitivity approaches including metabolomics and 
functional genomics.5 25–27 In addition, several of these 
newer approaches have demonstrated potential for 
identifying individuals with probable chronic carriage. 
Identification and treatment of chronic carriers in a popu-
lation would significantly improve our understanding of 
disease dynamics and allow targeted treatment strategies 
to reduce community transmission of infection.
Furthermore, while using these new diagnostic tests in 
comprehensive passive surveillance or even active surveil-
lance programmes will identify acute cases of typhoid 
disease, the incidence rate of subclinical infection and 
exposure is unknown. These data are likely essential 
to understanding pathogen transmission as well as the 
development and maintenance of immunity against clin-
ical disease12 and are likely only to be obtainable through 
the use of seroepidemiological methods. Previous seroep-
idemiological studies have examined the cross-sectional 
age-stratified prevalence of antibodies to the S Typhi 
flagellar (H) antigen in Santiago, Chile,28 and serum 
bactericidal antibody in Kathmandu, Nepal.29 Also, 
high-antibody titres to the Vi (Vi capsular polysaccharide; 
virulence factor) antigen of S Typhi measured by aggluti-
nation assay have been used to estimate chronic carrier 
frequency in population-based studies,30–32 although 
these studies were not universally successful at identifying 
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chronic carriers.33 Improvements in serological assays 
and the discovery of a newer generation of diagnostic 
antigens34 suggest that population-based serosurveillance 
studies, especially using longitudinal measurements, may 
provide key data regarding the incidence of subclinical 
infection with the bacterial agents of enteric fever and the 
prevalence of chronic carriers.
Transmission
Closely related to the estimate of incidence is the contri-
bution of different typhoid states to ongoing transmission 
within a community. Acute cases of enteric fever, individ-
uals with subclinical infection, as well as chronic carriers 
likely all contribute to the transmission and maintenance 
of S Typhi and S Paratyphi A in endemic areas, but not 
to the same degree. This is an essential area of further 
research, particularly given the negative impact trans-
mission from chronic carriers could have on the indirect 
protection afforded by typhoid vaccines.12 The impor-
tance of ‘short cycle’ transmission via contaminated food 
and water in the immediate environment versus ‘long 
cycle’ transmission via the contamination of community 
water sources is also an area of direct relevance in the 
control of typhoid fever, primarily through non-vaccine 
public health interventions including water and sanita-
tion hygiene (WASH) improvements.
Bacterial genome variation
The enteric fever agents S Typhi and S Paratyphi A, while 
genetically distinct from other serovars of Salmonella 
enterica, exhibit low genetic diversity and whole-genome 
sequence analysis is required to uncover patterns 
of genetic relatedness between isolates.35–37 These 
techniques have been used previously to track the devel-
opment and spread of antibiotic resistance on a global 
scale6 and have shown potential to accurately track trans-
mission links between individuals, specifically within 
affected households, in addition to the broader commu-
nity.38 One use of this high-resolution typing previously 
has been to determine whether isolates obtained from 
those with acute infection are distinct from those found 
in chronic gall bladder carriers.39
Host susceptibility
While environmental risk factors for enteric fever 
acquisition are thought to be relatively well under-
stood, recent evidence has emerged implicating genetic 
factors in host susceptibility to infection.35 36 Many early 
typhoid genetic susceptibility studies reporting candi-
date genes were limited by small sample sizes and choice 
of controls; a recent large-scale genome-wide association 
study. however, has identified a specific locus (HLA-
DRB1*405) which confers fivefold protection against 
developing typhoid fever.35 How genetic variation at this 
site influences protection against typhoid is still under 
investigation, but may result in functional differences 
in MHC class II amino acid sequences; in turn, this 
may influence S Typhi epitope selection and antigen 
presentation or the scale and format of the host’s T cell 
response.
Vaccines
Vaccines currently available for typhoid are either oral 
live-attenuated bacterial strains or are derived from the 
S Typhi polysaccharide capsule, called Vi; there are no 
licensed vaccines against S Paratyphi A or non-typhoidal 
salmonellae (NTS). Despite recommendations for their 
use, these vaccines have only sparsely been introduced 
in high-prevalence settings.7 40 The reasons for this are 
unclear, but likely include failure of prioritisation and a 
short fall in advocacy, in addition to technical deficiencies 
of the vaccines themselves. One common reason cited is 
the T-cell-independent nature of the immune response 
to the Vi polysaccharide vaccine; this renders the vaccine 
of little use in young children below the age of 2 years. In 
addition, this feature means that the immune response 
does not boost, requiring repeat vaccination to be admin-
istered every 3–5 years. As with other thymus-independent 
vaccines, to overcome this problem the Vi capsule may 
be chemically conjugated to a protein carrier,8 as has 
successfully been done with conjugation of Vi to Pseu-
domonas aeruginosa exotoxin A.9 Despite demonstrating 
good immunogenicity and efficacy in field trials,10 41 the 
vaccine is still unlicensed. Newer Vi-conjugate vaccines 
are in development and have progressed to assessment 
in field trials,42 43 and the Oxford human typhoid chal-
lenge model.44 Recent data from the challenge models 
suggest that the Vi response elicited by the vaccine is high 
and likely to be protective, at least in naive healthy adult 
volunteers with no immunity or those with history of 
infection.44 Furthermore, a recent study in Indian school-
children found a vaccine efficacy of 100% (95% CI 97.6% 
to 100%) after a single dose of Vi conjugated to tetanus 
toxoid during the first year of follow-up.43
The key issue remaining, once safe, well-tolerated, 
immunogenic vaccines become widely available, is how 
best to implement them in endemic settings. Currently 
available surveillance data from most regions are insuf-
ficient to demonstrate the age band with the highest 
incidence of enteric fever.45 Designing vaccination strat-
egies to cover the years during which children are most 
at risk and generating indirect protection by preventing 
infection among those age groups driving transmission 
could be facilitated through the use of well-informed 
mathematical modelling.
THe STraTaa STudy: raTionale and aimS
The Strategic Typhoid alliance across Africa and 
Asia (STRATAA) study draws together an international 
team of investigators, field sites, laboratories and research 
institutes to address many of the key outstanding ques-
tions described above regarding the burden of enteric 
fever and Salmonella exposure in endemic regions, the 
mechanisms of susceptibility and infection transmis-
sion. These have been identified as key uncertainties in 
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Table 1 Overarching objectives of the Strategic Typhoid alliance across Africa and Asia study
Primary To characterise the burden of enteric fever at three urban sites in Africa and Asia
Secondary Assess the burden/incidence of enteric fever
Assess the seroincidence of infection
Assess host factors affecting burden/incidence/transmission of enteric fever
Assess effect of pathogen genetics on burden/incidence/transmission of enteric fever
Develop diagnostic tools for rapid and consistent typhoid diagnosis
Develop transmission modelling and modelling of vaccine introduction impact
Tertiary objectives Strengthen research capacity in enteric fever endemic regions
Provide data to appropriate institutes and governments to advocate vaccine implementation
To characterise the burden of invasive non-typhoidal salmonellae and other invasive pathogens at an 
urban site in Malawi, Africa
mathematical models.11–13 By conducting field studies 
of the epidemiology and burden of enteric fever across 
three sites with distinct epidemiological profiles and 
applying state-of-the-art molecular methods, the goal 
of the STRATAA study is to collect the data needed to 
enhance our understanding of pathogen transmission, 
exposure and susceptibility. These data can then be used 
to rigorously parameterise and validate models for the 
transmission dynamics of the agents of enteric fever, such 
that these models can then be used to evaluate different 
vaccination strategies and, importantly, help predict the 
expected impact resulting from the direct and indirect 
effects of vaccine introduction. These and other over-
arching objectives of the STRATAA study are listed in 
table 1.
To deliver on these objectives, the following studies will 
be performed in parallel at each of the three chosen field 
sites, starting in May 2016 with activities continuing until 
October 2018. First, in a well-defined population catch-
ment of approximately 100 000 individuals, a detailed 
demographic census survey will be undertaken. Second, 
in healthcare facilities used by the census population 
(as confirmed through a healthcare utilisation survey) 
prospective passive surveillance to detect cases of enteric 
fever will be performed. Third, a seroincidence study will 
be conducted in an age-stratified sample of the census 
population at each site, collecting blood samples at inter-
vals to estimate the rate of seroconversion to typhoidal 
Salmonella antigens and hence the rate of subclinical/
asymptomatic exposure to these bacteria in the general 
population.
To meet the further objectives, which include evalu-
ating diagnostic tests, identifying antimicrobial resistance 
patterns, exploring host susceptibility and bacterial viru-
lence/genomic variation, biological samples, specimens 
and metadata will be collected during these individual 
studies. Data will be pooled to inform transmission 
dynamic and health economic models that can be used 
to help design future vaccine effectiveness studies and 
evaluate vaccine delivery strategies for widespread deploy-
ment.
STudy SiTeS
With known high incidence throughout South and 
Southeast Asia and a recent increase in reported cases 
from sub-Saharan Africa,46 47 three sites were selected 
from across Africa and Asia based on known high rates of 
enteric fever and the research capacity to deliver a study 
of this size and logistical complexity. The three sites differ 
in their epidemiological profiles and history of enteric 
fever incidence.
dhaka, Bangladesh
Mirpur is an area located within Dhaka Metropolitan 
area, Bangladesh (figure 1A), situated 7 km northwest of 
the International Centre for Diarrhoeal Disease Research, 
Bangladesh (icddr,b) main campus. The icddr,b manages 
two hospitals in Dhaka city, one in the main campus in 
Dhaka (the main hospital) and another in the Mirpur 
area known as Mirpur Treatment Centre comprising 
a 50-bed inpatient facility. As part of this programme, 
these and other health facilities (≥10 total) will be kept 
under careful surveillance for enteric fever in the census 
area. The total catchment area for the field site for the 
STRATAA study is 10.79 km2 with a total population of 
about 603 658 at a density of 55 946/km2. Approximately 
98% of residents have access to tap water supplied by the 
municipality while the remainder use wells, hand pumps 
and other sources such as ponds and rivers in the study 
area.
Previous data from blood culture surveillance revealed 
a high incidence of disease within Dhaka, with the 
burden particularly high in children under 5 years of age 
(estimated at 18.7 episodes/1000 person-years in this age 
group). The current S Typhi:Paratyphi ratio is approxi-
mately 5:1. Typhoid fever is reported throughout the 
year but peaks during the monsoon season.48 49 Of note, 
15% of S Typhi isolates are multi-drug resistant (MDR) 
and around 97% isolates are resistant to nalidixic acid50; 
extended-spectrum beta-lactamase-producing organisms 
have also been isolated from enteric fever patients in this 
setting.
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Figure 1 Description of the Strategic Typhoid alliance 
across Africa and Asia study field sites, demonstrating 
(i) the location of the three sampling sites in (A) Mirpur 
(Dhaka, Bangladesh), (B) Ndirande (Blantyre, Malawi) and 
(C) Patan (Kathmandu, Nepal); (ii) the historical number of 
typhoid cases detected per month at each site (blue box 
marks the annual monsoon season). S Typhi, Salmonella 
enterica serovar Typhi; S Paratyphi A, Salmonella enterica 
serovar Paratyphi A.
Blantyre, malawi
Ndirande is a large urban township on the outskirts of 
Blantyre city, Malawi, 6 km from the main referral hospital 
(figure 1B). It has a young population of around 100 000 
people spread over 6.77 km2. It is serviced by one health 
clinic staffed by clinical officers. It has high reported 
rates of typhoid fever along with a population HIV preva-
lence of around 18%.51Queen Elizabeth Central Hospital 
(QECH) in Blantyre, Malawi, is the government-funded 
hospital for Blantyre district, serving a local population of 
1.3 million persons and provides tertiary care to southern 
Malawi.
NTS have previously been the most common cause of 
invasive bloodstream infections in Blantyre,52 but since 
2011 there has been a rapid increase in the number of 
S Typhi cases seen at QECH, from approximately 14/
year between 1998 and 2010 to 782 in 2014.46 Much of 
this increase has been due to the emergence of the H58 
clone and is associated with an MDR phenotype.47 53 
This outbreak appears unrelated to HIV infection, but 
has resulted in high rates of mortality (2.5% adult and 
paediatric) despite the availability of fluoroquinolone 
antibiotics.47 In this setting, enteric fever is seasonal, 
with the peak number of cases seen at the end of the wet 
season and during the early dry season when the preva-
lence of malnutrition is also highest.
Patan, nepal
Patan is located within the Lalitpur Sub-Metropolitan 
City within the Kathmandu Valley, Nepal (figure 1C). 
The population is generally poor, with most living in 
overcrowded conditions and obtaining their water from 
stone spouts or sunken wells. Patan Hospital is a 318-bed 
government hospital providing emergency and elective 
outpatient and inpatient services to this area. The local 
catchment population of the hospital is approximately 
200 000 people in about 20 km2, with a population density 
of 8000/km2; there is a high rate of immigration for 
employment, particularly young males from rural areas. 
Enteric fever is frequently managed in the outpatient 
clinic at Patan Hospital, which has approximately 200 000 
outpatient visits annually.
Uptake of typhoid Vi vaccination is limited and natural 
exposure/subclinical infection is common.29 Approxi-
mately 400 culture-confirmed cases of enteric fever are 
diagnosed at Patan Hospital each year, with a peak during 
the monsoon months. The current S Typhi:Paratyphi A 
ratio is approximately 1:1.54 Antimicrobial resistance 
is more commonly observed in S Paratyphi A isolates; 
however, emergence of fluoroquinolone-resistant S Typhi 
isolates has also been recently identified,55 whereas MDR 
strains of either serovar are rare.38
meTHodS
Population census
In order to accurately calculate an incidence rate of 
typhoid fever for each of the study sites, a demographic 
census will be performed at baseline and repeated at 2 
years. The objective of the census is to identify/char-
acterise the source population corresponding to the 
catchment areas for the passive surveillance sites described 
below and estimate the person-time under surveillance.
Census data will be updated with births, deaths and 
migrations every 6 months in Dhaka and Patan, and 
at 2 years in Blantyre. The number of participants for 
the demographic census survey in each site needed 
to produce a two-sided 95% CI with a precision (half-
width) of 50% for the anticipated typhoid incidence rate 
detected through passive clinical surveillance has been 
calculated (table 2). The necessary catchment population 
size is driven by the size required to estimate the expected 
incidence rate in the 0–4-year-old age group, which is esti-
mated to be approximately 10% of the total population 
in each site.
The census will take place within a demarcated 
geographic area that is a known catchment population for 
the surveillance sites (figure 1). In total, at least 100 000 
individuals will be enumerated from ≥20 000 house-
holds. The head/key informant within the household 
will provide written informed consent to take part in the 
study. Information on all residents within the household 
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Table 3 Sample size calculations for the serological surveys to estimate age-specific rates of high titres of serum IgG anti-
H(d) antibodies 
Anticipated 
seroincidence 
(%)
Initial 
samples (n)
Anticipated 
number of 
events
Follow-up 
samples (n)*
Events 
detected (n)
Binomial exact
(95% CI)
Probability of 
observing 0 
events
0–4 years 0.2 2500 5 2000 4 0.0005 to 0.0051 0.0182
5–9 years 0.4 1300 5.2 1040 4 0.0010 to 0.0098 0.0155
10–14 years 0.8 800 6.4 640 5 0.0025 to 0.0181 0.0059
>14 years 0.2 3900 7.8 3120 6 0.0007 to 0.0042 0.0019
Total 8500 24.2 6800 19
Assumes age-stratified individual sampling; also accounts for detection of 1% chronic carriage rate in those aged ≥10 years.
*Assuming 5% migration and 15% refusal.
Table 2 Sample size required for the target populations in 
the three sites to estimate annual, blood culture-confirmed 
typhoid incidence in passive clinical surveillance
Age groups 
(years)
Anticipated typhoid 
incidence per 1000 
persons*
Precision or 
half-width
Sample 
size 
required
0–4 1.5 0.75 10 125
5–14 1.0 0.5 15 119
>14 0.5 0.25 29 801
*Assumed age-specific incidence rates (based on data from 
Dhaka, Bangladesh, Delhi, India, and Dong Thap, Vietnam).
at the time of the census will be gathered from the head 
of the household/key informant.
A household is defined as individuals living in the same 
dwelling or compound and sharing food from the same 
kitchen. A household member is considered to have 
migrated out if she/he has left the household and does 
not intend to come back within 6 months of the time she/
he left. A person is considered to have migrated in if she/
he was not previously included in the list of household 
members and intends to live in the household for the 
next 6 months. At enrolment, the head of each household 
will be made aware of the passive surveillance component 
of the study and encouraged to use the field-site facilities 
capturing acute febrile illnesses, including acute enteric 
fever cases. The characterised census population will form 
the sampling frame for the further components (passive 
surveillance, healthcare utilisation/WASH surveys and 
serosurvey) described below.
Passive surveillance
The passive surveillance component of STRATAA is 
designed to capture cases of febrile disease occurring in 
each of the three census populations. Patients presenting 
to any of the clinical surveillance sites with a history of 
subjective fever >72 hours or objective fever >38.5°C on 
presentation will be approached for enrolment.
An index case will be defined as an individual with a 
blood culture result confirming infection with S Typhi or 
S Paratyphi A (or NTS in Malawi), and whose household 
is included in the census survey. These cases will be used 
to calculate the disease incidence in each of the three 
census sites. Consenting individuals will have samples 
of blood, urine and stool collected to determine a diag-
nosis of S Typhi, S Paratyphi A or NTS and to provide 
material for the further diagnostic and genetic aims of 
the study (see online supplementary table 1). Patients not 
resident in the census area will be enrolled as additional 
cases for the laboratory and genetic components of the 
programme if written consent is provided.
Healthcare utilisation and water, sanitation and hygiene 
surveys
To characterise the healthcare-seeking behaviour of 
individuals living in the census areas, at least 735 house-
holds will be randomly selected from the census area at 
each site to participate in a healthcare utilisation survey. 
Data will be collected from the head of the household/
key informant to describe the actual and hypothetical 
usage of healthcare facilities for febrile episodes. The 
aim of this component is to estimate the per cent of cases 
(fulfilling the fever case definition) in each age stratum 
(0–4 years, 5–14 years and >14 years of age) who would or 
would not seek attention at one of the designated passive 
surveillance health facilities. Additional data regarding 
sanitation and hygiene facilities and usage will also be 
collected. Annual data collection periods will coincide 
with the peak typhoid season at each of the three sites.
Serosurveys
To estimate the seroincidence and seroprevalence of clin-
ical (both formally diagnosed and undiagnosed cases) 
and subclinical infection or exposure to S Typhi and S 
Paratyphi, systematic serosurveillance will be performed 
at each site. Blood samples will be collected at baseline 
and 3 months later, with sample collection initiated in 
an ongoing basis over the course of 1 year (table 3). To 
identify participants for the serosurvey, an age-stratified 
approach will be used to randomly select individuals from 
the census population from each age group. Suitable 
participants will be enrolled by field workers; where the 
individual identified is not available, a household member 
in the same age group will be selected. Where this is not 
possible, further households will be randomised into this 
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component to ensure adequate numbers of individuals in 
the different age groups.
Seroincidence (indicative of recent infection) will be 
calculated by measuring the rate of seroconversion to 
anti-H(d) (anti-flagellin) IgG and other acute-phase anti-
bodies between both time points, with the denominator 
consisting only of individuals sampled twice and seroneg-
ative at the first time point.56
The seroprevalence of anti-Vi IgG will also be measured 
at baseline to identify individuals who could be poten-
tial chronic carriers. Previous studies have used high 
anti-Vi IgG antibody levels in serum as a marker of 
chronic carriage, and our aim is to use a recently vali-
dated/approved anti-Vi ELISA method to determine 
possible rates of chronic carriage across the three popula-
tions.32 57 58 In order to validate this method and to identify 
possible chronic carriers in the population (in addition 
to identifying whether there may be specific host genetic 
risk factors for chronic carriage), those individuals with a 
‘high’ serum anti-Vi IgG titre will be reapproached and 
asked to provide two stool samples within 48 hours. With 
the agreement of relevant local ethics committees, iden-
tified chronic carriers (confirmed high anti-Vi IgG serum 
sample with a positive stool culture) will be treated with 
antibiotics for chronic carriage and clearance of bacterial 
shedding will be confirmed.
Household contacts
To further investigate possible transmission links, 
household contacts of index cases presenting with 
blood culture-confirmed S Typhi or S Paratyphi A 
infection will be identified through the census data 
collection and approached to take part in this compo-
nent of the study. Up to five members of the household, 
with consent, will be asked to provide a blood and stool 
sample at the time of discharge of the index case, a 
further stool sample at 1 month and repeat serology at 
6 months (see online supplementary table 1), and asked 
about the occurrence of symptoms. These samples will be 
investigated to identify those with subclinical infection or 
possible chronic carriers. Secondary attack rates for the 
occurrence of symptomatic infection will be estimated. If 
serology suggests chronic carriage in a household contact, 
additional blood and stool samples will be collected to 
confirm this, and antimicrobial treatment to eradicate 
carriage will be proposed.
Those individuals who are identified as shedding 
bacteria but without high serum anti-Vi IgG levels will be 
followed up at a 1-year interval to repeat stool culture. 
Repeat blood samples will be collected from household 
contacts approximately 3 months after initial sampling 
to explore whether rates of seroconversion are higher 
in these individuals compared with those in the general 
population. At least 73 households of index cases are 
expected to be enrolled in this component of the study.
In a similar approach to the acute cases of typhoid 
infection, where chronic carriers are identified from 
the serosurveys, household transmission studies will 
be performed among household contacts of possible 
chronic carriers (ie, those with a ‘high’ serum anti-Vi IgG 
titre). A one-time attempt will be made to enrol up to 
five members of the household, sampling serology and 
stool looking for evidence of typhoid infection. This will 
provide data on secondary attack rates for both acute and 
chronic typhoid states.
data management and analysis
Census and serosurvey data collection forms will be devel-
oped through a structured iterative process and then 
implemented using Open Data Kit,59 a system enabling 
electronic mobile data collection, with customisations 
by Nafundi, USA, on Android-based tablets. Each house-
hold within the census will be assigned a unique study 
ID and geo-located using GPS where possible; individuals 
will be given a member number within the household. 
This information will be collected by local enumerators 
over a 1–4-month period via these forms and adapted 
to the three geographic settings. Data will be uploaded 
onto MySQL databases, where SQL routines will be run 
nightly to enforce data cleaning on critical variables 
beyond ODK’s validation routines. Daily anonymised 
data will be backed up from the three sites centrally. For 
the passive surveillance and household contacts studies, a 
combination of tablet and paper-based case report forms 
will be used to capture the data. Data from paper forms 
will be transcribed onto electronic databases using Open 
Clinica.60 Database reports and descriptive analyses will be 
generated weekly. To assess efficiency and quality of data 
capture, the volume, accuracy and time of data collection 
can be quantified.
The distribution and burden of enteric illness is likely 
to vary between countries and thus analyses will be 
conducted separately for each country. Where data are 
combined across countries, an adjustment for country 
differences will be included in statistical models.
eTHicS
Written informed consent was obtained from the head of 
each household (as the ‘key informant’) on behalf of the 
entire household in the demographic census and health-
care utilisation surveys. In each of the other components, 
individual written informed consent was obtained from 
individuals over the age of 18 or by a parent/guardian 
from individuals below this age with additional assent 
sought from those aged between 11 and 17 years.
This protocol has received ethics approval from the 
Oxford Tropical Research Ethics Committee, the Mala-
wian National Health Sciences Research Committee and 
University of Malawi Research Ethics Committee, the 
Nepal Health Research Council and the icddr, b Institu-
tional Review Board.
diSSeminaTion
We hope to make the results from these studies widely 
available and plan to disseminate our analyses in 
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international peer-reviewed journals. Investigators will be 
involved in reviewing drafts of the manuscripts, abstracts, 
press releases and any other publications arising from the 
study. Furthermore, data from these studies will also be 
used in the submission of postdoctoral theses.
communiTy PuBlic engagemenT
A collection of specific activities engaging the local popu-
lation with both the subject of typhoid fever and the 
activities of the study have been carried out. In Malawi, 
for example, community leaders have been informed 
and consulted on certain aspects of the study, shown 
the proposed activities of study teams and given tours 
of research facilities. There has been engagement with 
various forms of media disseminating information on the 
importance of typhoid and study aims. In Nepal, field 
staff have been given detailed information to communi-
cate to the local populations.
Further activities are planned to ensure the local popu-
lations are informed and engaged.
diScuSSion
The STRATAA study is a comprehensive multicentre study 
aiming to improve understanding of typhoidal Salmonella 
infection in high-risk endemic populations. This study 
has been designed to answer key questions and data gaps 
identified through an innovative application of recent 
mathematical modelling. These gaps include measuring 
the burden of age-stratified disease, identifying the rela-
tive contribution of asymptomatic/subclinical Salmonella 
infection/exposure and estimating the contribution 
to ongoing transmission from the chronic carrier state. 
These data will inform further modelling required to 
develop and optimise disease control and prevention 
strategies that will eventually lead to disease elimination.
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